Ranjan Kumar Acharyya
Biochemistry, Genetics and Molecular Biology · University of Michigan
Publications
33
Citations
426
Est. group size
~17
Recurring co-author estimate
Active years
11
Publishing since 2016
Typically publishes in teams of ~8 · 33% small-team papers (≤3 authors) · across 10 venues
- Discovery of SD-2301 as a Highly Potent and Selective PROTAC STAT3 Degrader Capable of Achieving Complete Tumor Regression with Single Administration
Journal of Medicinal Chemistry · 2026
- Discovery ofSD-2301 as a Highly Potent and SelectivePROTAC STAT3 Degrader Capable of Achieving Complete Tumor Regressionwith Single Administration
Figshare · 2026
- Discovery ofSD-2301 as a Highly Potent and SelectivePROTAC STAT3 Degrader Capable of Achieving Complete Tumor Regressionwith Single Administration
Figshare · 2026
- Discovery and Characterization of PVTX-321 as a Potent and Orally Bioavailable Estrogen Receptor Degrader for ER+/HER2– Breast Cancer
Journal of Medicinal Chemistry · 2025
- Correction to “Discovery of ERD-1233 as a Potent and Orally Efficacious Estrogen Receptor PROTAC Degrader for the Treatment of ER+ Human Breast Cancer”
Journal of Medicinal Chemistry · 2025
- Abstract B132: SD-1240, a VHL-based STAT3 degrader, induces optent and selective STAT3 depletion and suppresses tumor growth in ALCL preclinical models
Molecular Cancer Therapeutics · 2025
- Orally Bioavailable Proteolysis-Targeting Chimeras: An Innovative Approach in the Golden Era of Discovering Small-Molecule Cancer Drugs
Pharmaceuticals · 2024
- Discovery of ERD-1233 as a Potent and Orally Efficacious Estrogen Receptor PROTAC Degrader for the Treatment of ER+ Human Breast Cancer
Journal of Medicinal Chemistry · 2024
- Abstract 4510: Potent and orally efficacious PROTAC degraders of estrogen receptor α (ERα)
Cancer Research · 2024
- Abstract 3881: Discovery of highly potent, selective and efficacious STAT3 PROTAC degraders capable of achieving long-lasting tumor regression
Cancer Research · 2024
- Abstract 4519: Discovery of highly potent, selective and efficacious STAT3 PROTAC degraders capable of achieving complete tumor regression
Cancer Research · 2024
- Abstract 6057: Evaluation of a highly potent and selective STAT3 degrader as a new class of immunotherapy
Cancer Research · 2024
- Abstract 4509: Discovery of potent and highly efficacious STAT3 PROTAC degraders capable of achieving long-lasting tumor regression
Cancer Research · 2024
- Synthetic studies towards naturally occurring γ-( <i>Z</i> )/( <i>E</i> )-alkylidenebutenolides through bimetallic cascade cyclization and an adventitious photoisomerization method
Organic & Biomolecular Chemistry · 2022
- Asymmetric Synthesis of 1,2-Dihydronaphthalene-1-ols via Copper-Catalyzed Intramolecular Reductive Cyclization
Organic Letters · 2020
- Journal of Medicinal Chemistry×10
- Cancer Research×5
- The Cambridge Structural Database×5
- Organic & Biomolecular Chemistry×3
- Figshare×2
- Zhixiang Chen
Biochemistry, Genetics and Molecular Biology · University of Michigan
- Hoda Metwally
Biochemistry, Genetics and Molecular Biology · University of Michigan
- Longchuan Bai
Biochemistry, Genetics and Molecular Biology · University of Michigan
- Xiang Liu
Biochemistry, Genetics and Molecular Biology · University of Michigan
- Brittany Sandoval
Biochemistry, Genetics and Molecular Biology · The Ohio State University
This profile was generated automatically from public scholarly data (OpenAlex). Group size and activity levels are estimates derived from co-authorship patterns.
Last updated Jul 25, 2026.
Claim or correct this profile